Back to Search
Start Over
Reporting of Demographics & Subgroup Analyses in Premarketing Studies of FDA Approved High-Risk Cardiovascular Devices, 2014–2022.
- Source :
- Medical Devices: Evidence & Research; Apr2024, Vol. 17, p165-172, 8p
- Publication Year :
- 2024
-
Abstract
- Abstracted detailed demographic data about the age, sex, race, ethnicity, and socioeconomic position of study participants. We also assessed the presence and results of subgroup analyses to understand the safety and effectiveness of devices across trial populations. Results: Analysis of 92 pivotal studies revealed that age and sex were reported in 96.7% of the studies, while race and ethnicity were reported in 71.7% and 58.7%, respectively. However, only 7.9% of studies explicitly detailed the participation of older adults (≥ 65 years) and no studies reported patients' socioeconomic position. Subgroup analyses by sex were conducted in 70.7% of studies, with 12.3% reporting significant differences. In contrast, analyses by race and ethnicity were performed in only 12.0% of the studies, with 9.1% reporting significant differences. Conclusion: Approximately one-third of pivotal studies for high-risk cardiovascular devices approved by the FDA from 2014 to 2022 did not report the race of study participants, nearly 40% did not report ethnicity, and more than 90% did not report the participation of older adults (≥ 65 years). Subgroup analyses were infrequently conducted by age or race and ethnicity. There is a need for better trial demographic reporting and conduct of subgroup analyses in premarketing studies to ensure the safety and effectiveness of medical devices for all patients. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 11791470
- Volume :
- 17
- Database :
- Complementary Index
- Journal :
- Medical Devices: Evidence & Research
- Publication Type :
- Academic Journal
- Accession number :
- 177901494
- Full Text :
- https://doi.org/10.2147/MDER.S457152